에 대한 최신 뉴스 Schrodinger (NASDAQ:SDGR) 주식

Schrodinger

Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.

Schrodinger Inc

Nvidia-backed Recursion to acquire Exscientia in all-stock deal

The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion by then.

AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Medtronic (MDT – Research Report) and Schrodinger (SDGR – Researc...

Analysts Conflicted on These Healthcare Names: Medtronic (MDT) and Schrodinger (SDGR)

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030.

Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week

Nvidia-backed Recursion hurts AI biotechs on mixed data for lead drug

The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug Discovery Stocks Portfolio by 6.6% on the day. 

Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!

AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual sales in excess of $50B.

AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th

In a report released today, Steven Mah from TD Cowen maintained a Buy rating on Schrodinger (SDGR – Research Report), with a price target of $42.00...

TD Cowen Sticks to Its Buy Rating for Schrodinger (SDGR)

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual sales in excess of $50B.

AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week

ABCL

ABSI

BSGM

EXAI

NVDA

RLAY

RXRX

SDGR

Press Releases

Qiming's Nisa Leung Made the 2024 Forbes Midas List

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Schrödinger to Announce Second Quarter 2024 Financial Results on July 31

Schrödinger Launches Initiative to Significantly Expand Application of Computational Tools for Predictive Toxicology

Schrödinger Reports Strong Second Quarter 2024 Financial Results

Schrödinger to Present at Morgan Stanley Global Healthcare Conference

Kuehn Law Encourages Investors of Schrodinger, Inc. to Contact Law Firm

BILI

GPCR

ZLAB

American Well Corporation Class A Common Stock

American Well

CareCloud

Certara

Definitive Healthcare Corp. - Class A Common Stock

Definitive Healthcare

Doximity

DarioHealth

Evolent Health

Forian

GoodRx Holdings, Inc. - Class A Common Stock

GoodRx Holdings

Health Catalyst

HealthStream

icad

LifeMD

MultiPlan Corporation Class A Common Stock

MultiPlan

OptimizeRx

Phreesia

Pheton Holdings Ltd - Class A Ordinary Shares

Pheton Holdings

Sharecare

Simulations Plus

Sophia Genetics

Streamline Health Solutions, Inc. - Common Stock

Streamline Health Solns

TruBridge

Teladoc Health

Veeva Systems

Waystar Holding

Morgan Stanley

Keybanc

Leerink Partners

Citigroup

Craig-Hallum

Comments

Schrodinger

뉴스

에 대한 최신 뉴스 Schrodinger (NASDAQ:SDGR) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌